Problems and possible solutions for therapy with statins

International Journal of Angiology

Volumn 22, Issue 2, 2013, Pages 75-82

  Whayne, Thomas F ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

cognition; coronary heart disease; diabetes mellitus; liver inflammation; low density lipoprotein cholesterol; statin myopathy; women and heart disease

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; UBIQUINONE;

ACUTE CORONARY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATTY LIVER; HEPATITIS; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRANSAMINASEMIA; ISCHEMIC HEART DISEASE; LIVER INJURY; LIVER PROTECTION; MORTALITY; MYOPATHY; PATHOGENESIS; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; TREATMENT RESPONSE;

EID: 84878379819     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0033-1343358     Document Type: Review

References (71)

1. Whayne T. F. Jr. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators. Angiology: 2011; 62 5 415 421
2. Silva M. A., Swanson A. C., Gandhi P. J., Tataronis G. R. Statin-related adverse events: a meta-analysis. Clin Ther: 2006; 28 1 26 35
3. Walsh J. M., Pignone M. Drug treatment of hyperlipidemia in women. JAMA: 2004; 291 18 2243 2252
4. Hayward R. A., Krumholz H. M. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes: 2012; 5 1 2 5
5. Whayne T. F. Jr. Assessment of low-density lipoprotein targets. Angiology: 2012; Jun 25. [Epub ahead of print], PMID: 22734087 [PubMed- as supplied by publisher].
6. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation: 2002; 106 25 3143 3421
7. McGuinness B., O'Hare J., Craig D., Bullock R., Malouf R., Passmore P. Statins for the treatment of dementia. Cochrane Database Syst Rev: 2010; 8 CD007514
8. Sattar N., Preiss D., Murray H. M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet: 2010; 375 9716 735 742
9. Ghatak A., Faheem O., Thompson P. D. The genetics of statin-induced myopathy. Atherosclerosis: 2010; 210 2 337 343
10. Phillips P. S., Haas R. H., Bannykh S., et al. Scripps Mercy Clinical Research Center Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med: 2002; 137 7 581 585
11. Nissen S. E., Tuzcu E. M., Schoenhagen P., et al. REVERSAL Investigators Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA: 2004; 291 9 1071 1080
12. Cannon C. P., Braunwald E., McCabe C. H., et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med: 2004; 350 15 1495 1504
13. Nissen S. E., Nicholls S. J., Sipahi I., et al. ASTEROID Investigators Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA: 2006; 295 13 1556 1565
14. Josan K., Majumdar S. R., McAlister F. A. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ: 2008; 178 5 576 584
15. Bruckert E., Hayem G., Dejager S., Yau C., Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther: 2005; 19 6 403 414
16. Pablos-Méndez A., Barr R. G., Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA: 1998; 279 3 222 225
17. Gazi I. F., Daskalopoulou S. S., Nair D. R., Mikhailidis D. P. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin: 2007; 23 9 2183 2192
18. Sager P. T., Melani L., Lipka L., et al. Ezetimibe Study Group Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol: 2003; 92 12 1414 1418
19. Crane F. L. Biochemical functions of coenzyme Q10. J Am Coll Nutr: 2001; 20 6 591 598
20. Gadarla M., Kearns A. K., Thompson P. D. Efficacy of rosuvastatin (5. mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol: 2008; 101 12 1747 1748
21. Kawashiri M. A., Nohara A., Tada H., et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther: 2008; 83 5 731 739
22. Gupta A., Thompson P. D. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis: 2011; 215 1 23 29
23. LaRosa J. C., He J., Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA: 1999; 282 24 2340 2346
24. Culver A. L., Ockene I. S., Balasubramanian R., et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med: 2012; 172 2 144 152
25. Kostis W. J., Cheng J. Q., Dobrzynski J. M., Cabrera J., Kostis J. B. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol: 2012; 59 6 572 582
26. Gutierrez J., Ramirez G., Rundek T., Sacco R. L. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med: 2012; 172 12 909 919
27. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet: 1994; 344 8934 1383 1389
28. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med: 1998; 339 19 1349 1357
29. Shepherd J., Cobbe S. M., Ford I., et al. West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med: 1995; 333 20 1301 1307
30. Downs J. R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA: 1998; 279 20 1615 1622
31. Ray K. K., Seshasai S. R., Erqou S., et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med: 2010; 170 12 1024 1031
32. Higgins J. P., Thompson S. G., Deeks J. J., Altman D. G. Measuring inconsistency in meta-analyses. BMJ: 2003; 327 7414 557 560
33. Redberg R. F. Update in cardiology: evidence published in 2010. Ann Intern Med: 2011; 154 8 549 553
34. Ridker P. M., Danielson E., Fonseca F. A., et al. JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med: 2008; 359 21 2195 2207
35. de Lorgeril M., Salen P., Abramson J., et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med: 2010; 170 12 1032 1036
36. Whayne T. F. Jr. Astronomical science or astronomical marketing? Clin Geriatrics: 2009; 17 36
37. Green L. A. Cholesterol-lowering therapy for primary prevention: still much we don't know. Arch Intern Med: 2010; 170 12 1007 1008
38. Brugts J. J., Yetgin T., Hoeks S. E., et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ: 2009; 338 b2376
39. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA: 1984; 251 3 351 364
40. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA: 1984; 251 3 365 374
41. Blankenhorn D. H., Johnson R. L., Nessim S. A., Azen S. P., Sanmarco M. E., Selzer R. H. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials: 1987; 8 4 356 387
42. Blankenhorn D. H., Nessim S. A., Johnson R. L., Sanmarco M. E., Azen S. P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA: 1987; 257 23 3233 3240
43. Buchwald H., Stoller D. K., Campos C. T., Matts J. P., Varco R. L. Partial ileal bypass for hypercholesterolemia. 20- to 26-year follow-up of the first 57 consecutive cases. Ann Surg: 1990; 212 3 318 329, discussion 329-331
44. Buchwald H., Varco R. L., Boen J. R., et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med: 1998; 158 11 1253 1261
45. Moriarty P. M. LDL-apheresis therapy. Curr Treat Options Cardiovasc Med: 2006; 8 4 282 288
46. Schonfeld G. The hypobetalipoproteinemias. Annu Rev Nutr: 1995; 15 23 34
47. Wiviott S. D., Cannon C. P., Morrow D. A., Ray K. K., Pfeffer M. A., Braunwald E. PROVE IT-TIMI 22 Investigators Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol: 2005; 46 8 1411 1416
48. Athyros V. G., Papageorgiou A. A., Mercouris B. R., et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin: 2002; 18 4 220 228
49. Hsia J., MacFadyen J. G., Monyak J., Ridker P. M. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol: 2011; 57 16 1666 1675
50. Grundy S. M., Cleeman J. I., Merz C. N., et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation: 2004; 110 2 227 239
51. Pascale A., Pais R., Ratziu V. An overview of nonalcoholic steatohepatitis: past, present and future directions. J Gastrointestin Liver Dis: 2010; 19 4 415 423
52. Athyros V. G., Tziomalos K., Gossios T. D., et al. GREACE Study Collaborative Group Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet: 2010; 376 9756 1916 1922
53. Han K. H., Rha S. W., Kang H. J., et al. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). J Clin Lipidol: 2012; 6 4 340 351
54. Wierzbicki A. S., Oben J. Nonalcoholic fatty liver disease and lipids. Curr Opin Lipidol: 2012; 23 4 345 352
55. Henninger C., Huelsenbeck J., Huelsenbeck S., et al. The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity. Toxicol Appl Pharmacol: 2012; 261 1 66 73
56. Rzouq F. S., Volk M. L., Hatoum H. H., Talluri S. K., Mummadi R. R., Sood G. K. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci: 2010; 340 2 89 93
57. Biondi E. Prescription of lipophilic statins to Alzheimer's disease patients: some controversies to consider. Neurol Sci: 2011; 32 2 195 201
58. Rojas-Fernandez C. H., Cameron J. C. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother: 2012; 46 4 549 557
59. Li G., Shofer J. B., Rhew I. C., et al. Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc: 2010; 58 7 1311 1317
60. Trompet S., van Vliet P., de Craen A. J., et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol: 2010; 257 1 85 90
61. Glasser S. P., Wadley V., Judd S., et al. The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study. Clin Cardiol: 2010; 33 5 280 288
62. Sabbagh M. N., Sparks D. L. Statins to treat Alzheimer's disease: an incomplete story. Expert Rev Neurother: 2012; 12 1 27 30
63. Freeman D. J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation: 2001; 103 3 357 362
64. Dalla Nora E., Passaro A., Zamboni P. F., Calzoni F., Fellin R., Solini A. Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study. J Endocrinol Invest: 2003; 26 1 73 78
65. Huptas S., Geiss H. C., Otto C., Parhofer K. G. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol: 2006; 98 1 66 69
66. Ridker P. M., Pradhan A., MacFadyen J. G., Libby P., Glynn R. J. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet: 2012; 380 9841 565 571
67. Colbert J. D., Stone J. A. Statin use and the risk of incident diabetes mellitus: a review of the literature. Can J Cardiol: 2012; 28 5 581 589
68. Jukema J. W., Cannon C. P., de Craen A. J., Westendorp R. G., Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol: 2012; 60 10 875 881
69. Navarese E. P., Buffon A., Andreotti F., et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol: 2013; Jan 24 [Epub ahead of print]. PMID: 23352266 [PubMed-as supplied by publisher].
70. Shah R. V., Goldfine A. B. Statins and risk of new-onset diabetes mellitus. Circulation: 2012; 126 18 e282 e284
71. Rocco M. B. Statins and diabetes risk: fact, fiction, and clinical implications. Cleve Clin J Med: 2012; 79 12 883 893